Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $226.76M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.95M
Average 1.29M
VNDA Operating Cash Flow
Cash generated by the company's core business operations during the period.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow grows, but more slowly than its trailing trend
Q1 FY2026 operating cash flow of $50.22M (cash outflow) rose 51.5% year over year, behind the +124.0% change in trailing-twelve-month operating cash flow. Sequentially, it rose 70.7% from the prior quarter.
Context
- Operating cash flow amounted to 50.6% of revenue in FY2025, up 42.7 pp from a year earlier.
- Operating cash flow increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +51.5% toward the trailing-twelve-month pace of +124.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (109.44M) USD
- Year-over-year change
- -594.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (109.44M) | -594.6% |
| FY2024 | 2024-12-31 | (15.76M) | -223.1% |
| FY2023 | 2023-12-31 | 12.8M | -60.0% |
| FY2022 | 2022-12-31 | 31.98M | -50.2% |
| FY2021 | 2021-12-31 | 64.21M | — |
Operating Cash Flow vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's LTM Mar 2026 operating cash flow of $126.51M is the 4th largest of the 11 companies compared; the peer median is $97.09M.
- Its year-over-year change of +124.0% is the 2nd highest of 11, against a peer median of +8.2%.
- Operating cash flow amounts to 58.1% of revenue for VNDA, versus a peer median of 1323.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $147.86M | +17.2% | +3.0% | — | |
| LTM Mar 2026 | $131.7M | +141.5% | +11.1% | 2295.2% | |
| LTM Mar 2026 | $127.99M | +14.3% | +119.6% | 350.7% | |
| LTM Mar 2026 | $126.51M | +124.0% | — | 58.1% | |
| LTM Mar 2026 | $109.23M | -44.6% | -12.2% | — | |
| LTM Mar 2026 | $101.54M | +2.2% | +13.9% | 5037.0% | |
| LTM Mar 2026 | $92.63M | +105.1% | — | — | |
| LTM Mar 2026 | $58.57M | -34.4% | — | 129.2% | |
| LTM Mar 2026 | $49.7M | -7.3% | +0.9% | — | |
| LTM Mar 2026 | $45.31M | +27.4% | +9.6% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $39.73M | -21.7% | +23.1% | — |
| Peer median (excluding VNDA) | $97.09M | +8.2% | +10.3% | 1323.0% | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 33.15M | 6.28M | 2.51M | (18.9M) | (220.47M) |
| Depreciation & Amortization | 2.84M | 2.73M | 3.01M | 8.13M | (950K) |
| Deferred Income Tax | 6.75M | 1.13M | (1.29M) | (6.48M) | 81.44M |
| Stock-Based Compensation | 15.37M | 16.28M | 14.04M | 12.43M | 9.47M |
| Change in Working Capital | 2.74M | 6.07M | (747K) | (6.56M) | 8.31M |
| Accounts Receivables | (2.47M) | (1.09M) | (707K) | (13.01M) | (7.46M) |
| Inventory | (2.23M) | (4.48M) | (771K) | (29K) | (3.47M) |
| Accounts Payables | 3.04M | 11.79M | (10.98M) | 1.71M | 15.82M |
| Other Working Capital | 4.4M | (151K) | 11.72M | 4.78M | 3.42M |
| Other Non-Cash Items | 3.37M | (507K) | (4.73M) | (4.38M) | 12.76M |
| Operating Cash Flow | 64.21M | 31.98M | 12.8M | (15.76M) | (109.44M) |
| Capital Expenditures | (552K) | (679K) | (383K) | (490K) | (998K) |
| Acquisitions (Net) | 0 | 0 | (100.67M) | (4.23M) | 0 |
| Purchases of Investments | (420.46M) | (349.26M) | (512.61M) | (364.77M) | (112.38M) |
| Sales of Investments | 344.32M | 399.86M | 601.6M | 352.06M | 208.24M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (76.7M) | 49.93M | (12.06M) | (17.43M) | 94.86M |
| Debt Repayment | 0 | 0 | 0 | (155K) | (1.99M) |
| Common Stock Issued | 3.55M | 734K | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | (915K) |
| Financing Cash Flow | 3.55M | 734K | 0 | (155K) | (2.91M) |
| Effect of Forex Changes | (85K) | 315K | 47K | (163K) | 126K |
| Net Change in Cash | (9.02M) | 82.96M | 792K | (33.51M) | (17.36M) |
| Free Cash Flow | 63.66M | 31.31M | 12.42M | (16.25M) | (110.44M) |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.